Summary
This 2023 study reports the development and optimisation of a microRNA-based companion diagnostic panel for predicting chemotherapy response in diffuse large B-cell lymphoma patients receiving R-CHOP treatment. By integrating molecular profiling of miRNA expression with clinical outcome data, the authors identified a discriminatory signature intended to support personalised treatment selection. The work exemplifies the application of molecular biomarkers to stratify oncology patients by predicted therapeutic benefit.
UK applicability
This molecular diagnostic approach could support precision oncology practice in UK NHS trusts managing DLBCL, potentially informing treatment selection and optimising chemotherapy efficacy. However, validation in UK patient cohorts and integration into clinical pathways would be required before routine implementation.
Key measures
microRNA expression signatures; R-CHOP treatment response prediction accuracy; discriminatory power of miRNA panels
Outcomes reported
The study identified and validated an optimised microRNA panel capable of predicting treatment response to R-CHOP chemotherapy in diffuse large B-cell lymphoma patients. The panel was developed through molecular profiling and clinical correlation to enable stratification of patients by expected therapeutic benefit.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.